Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,818 | -19,756 | -11,039 | -39,754 | -29,513 |
| Depreciation Amortization | 4 | 2 | 1 | 4 | 3 |
| Other Working Capital | 2,742 | 1,930 | 2,494 | 699 | 29 |
| Other Operating Activity | 4,607 | 3,923 | 2,455 | -704 | -1,956 |
| Operating Cash Flow | $-18,465 | $-13,901 | $-6,089 | $-39,755 | $-31,437 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | -2 | -4 | -10 | -11 |
| Investing Cash Flow | $-4 | $-2 | $-4 | $-10 | $-11 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 786 | 786 | N/A | 10,020 | N/A |
| Debt Repayment | -2,762 | -90 | N/A | -518 | N/A |
| Common Stock Issued | 8,122 | 8,122 | 2,545 | 22,712 | 22,610 |
| Other Financing Activity | 1,171 | 0 | 0 | 0 | -518 |
| Financing Cash Flow | $7,317 | $8,818 | $2,545 | $32,214 | $22,092 |
| Beginning Cash Position | 20,054 | 20,054 | 20,054 | 27,605 | 27,605 |
| End Cash Position | 8,902 | 14,969 | 16,506 | 20,054 | 18,249 |
| Net Cash Flow | $-11,152 | $-5,085 | $-3,548 | $-7,551 | $-9,356 |
| Free Cash Flow | |||||
| Operating Cash Flow | -18,465 | -13,901 | -6,089 | -39,755 | -31,437 |
| Capital Expenditure | -4 | -2 | -4 | -10 | -11 |
| Free Cash Flow | -18,469 | -13,903 | -6,093 | -39,765 | -31,448 |